The Global Exocrine Pancreatic Insufficiency Treatment Market was valued at USD 3 billion in 2025 and is estimated to grow at a CAGR of 6% to reach USD 5.3 billion by 2035.
Market growth is fueled by the rising prevalence of chronic pancreatitis, cystic fibrosis, and an aging population, combined with advancements in diagnostic technologies and pharmaceutical innovations. Enhanced diagnostic methods allow earlier detection of EPI, improving treatment outcomes and patient quality of life. Research increasingly focuses on identifying precise biomarkers to assess pancreatic function accurately. Low fecal elastase-1 levels serve as a reliable indicator of pancreatic insufficiency, offering a simpler, outpatient-friendly alternative to invasive procedures. EPI treatment involves medical and dietary management to replace deficient pancreatic enzymes essential for nutrient digestion and absorption. Timely intervention helps reduce symptoms, improve nutrient uptake, and significantly enhance overall patient well-being. The growing awareness of pancreatic disorders and the need for effective treatment solutions is further driving global demand for these therapies.
The pancreatic enzyme replacement therapy (PERT) segment accounted for USD 2.6 billion in 2025 and is projected to reach USD 4.6 billion by 2035. EPI occurs when the pancreas fails to produce or deliver sufficient digestive enzymes, leading to maldigestion and malabsorption. Common underlying conditions include chronic pancreatitis, pancreatic cancer, cystic fibrosis, and diabetes. PERT provides patients with oral administration of pancrelipase, a combination of lipase, protease, and amylase, to restore normal digestive function.
The abdominal pain segment held a 22.3% share in 2025. Abdominal pain is a frequent symptom of EPI, arising from insufficient enzyme production and incomplete digestion. PERT alleviates this discomfort by improving digestion and reducing undigested food accumulation in the intestines. Accurate dosing and timing of enzyme intake with meals are essential for effective symptom control.
U.S. Exocrine Pancreatic Insufficiency Treatment Market was valued at USD 1.62 billion in 2025. Rising incidences of pancreatic disorders, including pancreatic cancer and cystic fibrosis, are primary growth drivers. As the prevalence of these conditions continues to increase, the demand for advanced and effective EPI therapies is expanding, supporting further market growth in North America.
Prominent companies active in the Global Exocrine Pancreatic Insufficiency Treatment Market include Sun Pharmaceutical Industries, Zentiva Pharma, Nordmark Pharma, Abbott Laboratories, Viatris, Digestive Care, Essential Pharma, Eisai, AbbVie, VIVUS, and Nestlé. Companies in the EPI treatment sector are enhancing their market presence through targeted product innovation and portfolio expansion. Many are investing in next-generation enzyme formulations and combination therapies to improve efficacy and patient adherence. Research and development initiatives focus on identifying biomarkers and improving diagnostic tools, enabling earlier and more precise treatment. Strategic partnerships with healthcare providers and collaborations with research institutions strengthen credibility and market access. Manufacturers are also leveraging digital platforms and telemedicine solutions to educate patients and support treatment compliance. Expanding geographic presence in high-prevalence regions, optimizing supply chains, and aligning with regulatory standards ensures broader reach and trust.
This product will be delivered within 2-4 business days.
Market growth is fueled by the rising prevalence of chronic pancreatitis, cystic fibrosis, and an aging population, combined with advancements in diagnostic technologies and pharmaceutical innovations. Enhanced diagnostic methods allow earlier detection of EPI, improving treatment outcomes and patient quality of life. Research increasingly focuses on identifying precise biomarkers to assess pancreatic function accurately. Low fecal elastase-1 levels serve as a reliable indicator of pancreatic insufficiency, offering a simpler, outpatient-friendly alternative to invasive procedures. EPI treatment involves medical and dietary management to replace deficient pancreatic enzymes essential for nutrient digestion and absorption. Timely intervention helps reduce symptoms, improve nutrient uptake, and significantly enhance overall patient well-being. The growing awareness of pancreatic disorders and the need for effective treatment solutions is further driving global demand for these therapies.
The pancreatic enzyme replacement therapy (PERT) segment accounted for USD 2.6 billion in 2025 and is projected to reach USD 4.6 billion by 2035. EPI occurs when the pancreas fails to produce or deliver sufficient digestive enzymes, leading to maldigestion and malabsorption. Common underlying conditions include chronic pancreatitis, pancreatic cancer, cystic fibrosis, and diabetes. PERT provides patients with oral administration of pancrelipase, a combination of lipase, protease, and amylase, to restore normal digestive function.
The abdominal pain segment held a 22.3% share in 2025. Abdominal pain is a frequent symptom of EPI, arising from insufficient enzyme production and incomplete digestion. PERT alleviates this discomfort by improving digestion and reducing undigested food accumulation in the intestines. Accurate dosing and timing of enzyme intake with meals are essential for effective symptom control.
U.S. Exocrine Pancreatic Insufficiency Treatment Market was valued at USD 1.62 billion in 2025. Rising incidences of pancreatic disorders, including pancreatic cancer and cystic fibrosis, are primary growth drivers. As the prevalence of these conditions continues to increase, the demand for advanced and effective EPI therapies is expanding, supporting further market growth in North America.
Prominent companies active in the Global Exocrine Pancreatic Insufficiency Treatment Market include Sun Pharmaceutical Industries, Zentiva Pharma, Nordmark Pharma, Abbott Laboratories, Viatris, Digestive Care, Essential Pharma, Eisai, AbbVie, VIVUS, and Nestlé. Companies in the EPI treatment sector are enhancing their market presence through targeted product innovation and portfolio expansion. Many are investing in next-generation enzyme formulations and combination therapies to improve efficacy and patient adherence. Research and development initiatives focus on identifying biomarkers and improving diagnostic tools, enabling earlier and more precise treatment. Strategic partnerships with healthcare providers and collaborations with research institutions strengthen credibility and market access. Manufacturers are also leveraging digital platforms and telemedicine solutions to educate patients and support treatment compliance. Expanding geographic presence in high-prevalence regions, optimizing supply chains, and aligning with regulatory standards ensures broader reach and trust.
Comprehensive Market Analysis and Forecast
- Industry trends, key growth drivers, challenges, future opportunities, and regulatory landscape
- Competitive landscape with Porter’s Five Forces and PESTEL analysis
- Market size, segmentation, and regional forecasts
- In-depth company profiles, business strategies, financial insights, and SWOT analysis
This product will be delivered within 2-4 business days.
Table of Contents
Chapter 1 Methodology and Scope
Chapter 2 Executive Summary
Chapter 3 Industry Insights
Chapter 4 Competitive Landscape, 2025
Chapter 5 Market Estimates and Forecast, by Treatment, 2022-2035 ($ Mn)
Chapter 6 Market Estimates and Forecast, by Drug Type, 2022-2035 ($ Mn)
Chapter 7 Market Estimates and Forecast, by Symptom, 2022-2035 ($ Mn)
Chapter 8 Market Estimates and Forecast, by Distribution Channel, 2022-2035 ($ Mn)
Chapter 9 Market Estimates and Forecast, by Region, 2022-2035 ($ Mn)
Chapter 10 Company Profiles
Companies Mentioned
The companies profiled in this Exocrine Pancreatic Insufficiency Treatment market report include:- Abbott Laboratories
- AbbVie
- Digestive Care
- Essential Pharma
- Eisai
- Nestlé
- Nordmark Pharma
- Sun Pharmaceutical Industries
- Viatris
- VIVUS
- Zentiva Pharma
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 160 |
| Published | December 2025 |
| Forecast Period | 2025 - 2035 |
| Estimated Market Value ( USD | $ 3 Billion |
| Forecasted Market Value ( USD | $ 5.3 Billion |
| Compound Annual Growth Rate | 6.0% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
